Is 6-month GRACE risk score a useful tool to predict stroke after an acute coronary syndrome?

Belén Álvarez-Álvarez, Sergio Raposeiras-Roubín, Emad Abu-Assi, Cristina Cambeiro-González, Santiago Gestal-Romaní, Andrea López-López, Noelia Bouzas-Cruz, María Castiñeira-Busto, Ozoda Saidhodjayeva, Alfredo Redondo-Diéguez, Eva Pereira López, José María García-Acuña, José Ramón González-Juanatey

To cite: Álvarez-Álvarez B, Raposeiras-Roubín S, Abu-Assi E, *et al.* Is 6-month GRACE risk score a useful tool to predict stroke after an acute coronary syndrome? *Open Heart* 2014;1:e000123. doi:10.1136/openhrt-2014-000123

Received 13 March 2014
Revised 13 August 2014
Accepted 4 November 2014

CrossMark

Department of Cardiology,
University Clinical Hospital of
Santiago de Compostela,
Santiago de Compostela,
Spain

Correspondence to
Belén Álvarez Álvarez;
belenalvarez85@hotmail.com

ABSTRACT

Objectives: The risk of stroke after an acute coronary syndrome (ACS) has increased. The aim of this study was to do a comparative validation of the 6-month GRACE (Global Registry of Acute Coronary Events) risk score and CH₂DS₂VASc risk score to predict the risk of post-ACS ischaemic stroke.

Methods: This was a retrospective study carried out in a single centre with 4229 patients with ACS discharged between 2004 and 2010 (66.9±12.8 years, 27.9% women, 64.2% underwent percutaneous coronary intervention). The primary end point is the occurrence of an ischaemic stroke during follow-up (median 4.6 years, IQR 2.7–7.1 years).

Results: 184 (4.4%) patients developed an ischaemic stroke; 153 (83.2%) had sinus rhythm and 31 (16.9%) had atrial fibrillation. Patients with stroke were older, with higher rates of hypertension, diabetes, previous stroke and previous coronary artery disease. The HR for CH₂DS₂VASc was 1.36 (95% CI, 1.27 to 1.48, p<0.001) and for GRACE, HR was 1.02 (95% CI, 1.01 to 1.03, p<0.001). Both risk scores show adequate discriminative ability (c-index 0.63±0.02 and 0.60±0.02 for CH₂DS₂VASc and GRACE, respectively). In the reclassification method there was no difference (Net Reclassification Improvement 1.98%, p=0.69). Comparing moderate-risk/high-risk patients with low-risk patients, both risk scores showed very high negative predictive value (98.5% for CH₂DS₂VASc, 98.1% for GRACE). The sensitivity of CH₂DS₂VASc score was higher than the GRACE risk score (95.1% vs 87.0%), whereas specificity was lower (14.4% vs 30.2%).

Conclusions: The 6-month GRACE model is a clinical risk score that facilitates the identification of individual patients who are at high risk of ischaemic stroke after ACS discharge.

INTRODUCTION

Stroke after an acute coronary syndrome (ACS) is a rare complication. Although its incidence is higher in the first few days after ACS,¹ the risk of stroke continues with the

KEY QUESTIONS

What is already known about this subject?

▶ Patients, who survive an acute coronary syndrome (ACS), have an increased risk of stroke and therefore, a greater possibility of mortality. Most studies have assessed the incidence and predictors during admission, and during the first year of stroke post-ACS. Although there has been recently a reduction in incidence of strokes due to the advances in treatment and secondary prevention; 6-month GRACE (Global Registry of Acute Coronary Events) risk score is a useful tool to predict mortality and reinfarction. It is, however, not well defined in its ability to predict stroke after an ACS. Owing to the consequences of having an ACS, we propose this trial to assess the 6-month GRACE risk score in this setting.

What does this study add?

▶ Six-month GRACE risk score estimates mortality after discharge. This proved useful to determine the long-term risk of thrombotic events and was validated in large external data sets. So far, no studies have predicted the risk of ischaemic stroke after ACS. In our study, we want to conduct a comparative validation of the 6-month GRACE risk score to predict the risk of post-ACS ischaemic stroke.

How might this impact on clinical practice?

▶ Clinical practice does not have a useful tool to predict the risk of ischaemic stroke after ACS. It is important for the existence of a validated risk-standardised model to identify high-risk patients. Our study adds another utility to the 6-month GRACE risk score when it predicts thromboembolic risk. Then, 6-month GRACE risk score allows us to predict mortality, reinfarction and ischaemic stroke risk in the follow-up.

follow-up. Despite antithrombotic therapy, recent studies have shown a long-term rate of stroke after an ACS, between 1% and 4%.^{2–7}

Also the consequences of this complication are very serious. Owing to this, it is important to identify the patients with increased risk of stroke.

To date, there are two scores that allow us to estimate the thromboembolic risk of stroke in non-valvular atrial fibrillation (AF): CHADS₂⁸ and later, CHA₂DS₂VASc.⁹ Although these two risk scores were not specifically designed to predict stroke risk after an ACS, they were recently validated in this setting.¹⁰ In addition to these, there are several scores to estimate the thrombotic risk after an ACS. The GRACE (Global Registry of Acute Coronary Events) risk score is the most extended, and it has been validated to predict death and reinfarction after an ACS.^{11–13}

The aim of our study was to compare both risk scores, CHA₂DS₂VASc and 6-month GRACE risk score, to predict the long-term incidence of ischaemic stroke after an ACS.

METHODS

Data sources and samples

This was a retrospective study in which demographic, clinical and angiographic data, as well as data on management and in-hospital complications, had been prospectively collected and recorded in an electronic database. All patients with a diagnosis of ACS, admitted consecutively into our hospital between January 2004 and June 2010 were included in the study. ACS diagnosis was validated if the patient had new onset symptoms consistent with cardiac ischaemia and at least one of the following criteria: cardiac biomarkers above the higher normal laboratory limit, ST-segment deviation on ECG, in-hospital stress testing showing ischaemia or a known history of coronary vessel disease. Patients were classified as having acute myocardial infarction (AMI) with ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation ACS (NSTEMI-ACS; unstable angina and non-ST-segment elevation AMI). The initial cohort consisted of 4645 patients; 274 patients died during the in-hospital phase. Of the 4371 discharged patients, we excluded those patients in whom ACS was precipitated in the context of surgery, sepsis, trauma or cocaine consumption (n=41), and those with missing data for any variable of GRACE risk score (n=67). Of the 4263 remaining patients, 1-month follow-up was completed for 99.2% (34 patients without follow-up data). Thus, the final cohort was composed of 4229 patients. The study complies with the Declaration of Helsinki and was approved by the Clinical Research Ethics Committee of our hospital.

End point

The primary end point of this study was the occurrence of an ischaemic stroke during follow-up (median 4.6 years, IQR 2.7–7.1 years), confirmed through cerebral CT when deemed necessary by the attending neurologist. Patients were followed for a mean of 4.6 years (IQR 2.7–

7.1 years) after their discharge. Methods of follow-up involved one or more of the following: use of hospital records, hospital visits, phone call to the patient's general physician and/or phone call to the patient.

GRACE risk score calculation

The 6-month GRACE risk score was calculated for each patient by assigning the appropriate number of points for each of the nine prognostic variables that enter into the calculation: age, history of heart failure, history of AMI, heart rate and systolic blood pressure at admission, ST-segment depression, serum creatinine at admission, elevated myocardial necrosis markers or enzymes and lack of percutaneous coronary revascularisation during admission (Supplemental Data). Three risk categories were established using the cut-off points set out in the GRACE study. Therefore, in the low-risk category, the GRACE score was 27–99 points for STEMI and 1–88 for NSTEMI-ACS; in the intermediate risk category, the score for STEMI was 100–127 and 89–118 for NSTEMI-ACS; and in the high risk category, the score for STEMI was 128–263 and 119–263 for NSTEMI-ACS.

Statistical analysis

All analyses were performed using SPSS (V.17.0, SPSS Inc, Chicago, Illinois) and STATA V.13.0. Discrete variables are expressed as frequencies and percentages, and quantitative data are presented as the mean±SD. χ^2 Test was used to compare discrete variables and the Student t test to compare quantitative variables. The correlation between the risk scores was performed using Pearson test. A Cox proportional hazards model was used to estimate the HR and 95% CI of each variable in the GRACE and CHA₂DS₂VASc risk scores. Both stroke and death before ACS occurrence were regarded as competing risks using sub-HR (SHR).¹⁴ Cumulative stroke rates were analysed by the method of Kaplan-Meier (Log-rank test) for the different risk groups.

The c-index¹⁵ has been used as the measure for model discrimination, equivalent to the area under a receiver operating characteristic curve; this was used to determine the performance of GRACE and CHA₂DS₂VASc risk scores in predicting the follow-up stroke. Negative and positive predictive values for GRACE risk score were also computed for the moderate-risk/high-risk group versus low-risk group.

We also analyse the risk reclassification with Pencina's method.¹⁶ This allowed us to calculate the Net Reclassification Improvement (NRI). It is a fraction of net reclassification based on predictions with or without a marker, and it improves the sensitivity and specificity. A p value <0.05 was considered statistically significant.

RESULTS

Baseline characteristics and events

A total of 4229 patients were included in the analysis. The baseline characteristics are shown in table 1. The median

Table 1 Clinical characteristics, in-hospital management and treatment at discharge

Variables	Total population	Stroke	No stroke	p Value
Age (years)	66.9±12.8	71.3±10.2	66.7±12.9	<0.010
Female sex	27.9%	33.2%	27.6%	0.101
GRACE 6 months	112.9±33.4	123.8±30.5	112.5±33.5	<0.010
CHA ₂ DS ₂ VASc	2.7±1.9	3.4±1.8	2.6±1.8	<0.010
MDRD-4 (mL/min/1.73 m ²)	74.9±39.3	68.8±23.7	75.1±39.8	0.032
TNI peak (ng/mL)	28.9±123.8	20.8±40.6	29.3±126.2	0.366
Hypertension	57.1%	66.3%	56.7%	0.010
Diabetes	26.5%	35.9%	26.0%	0.003
Hypercholesterolemia	45.2%	46.2%	45.1%	0.779
Previous CAD	23.1%	29.9%	22.8%	0.026
Previous stroke	6.8%	14.1%	6.5%	<0.001
Previous atrial fibrillation	10.5%	16.8%	10.3%	0.004
Hospitalisation				
EF <40%	12.8%	14.1%	12.7%	0.576
STEMI	31.5%	27.7%	31.7%	0.256
Multivessel	37.4%	32.1%	37.7%	0.124
PCI	64.2%	56.5%	64.5%	0.027
At discharge				
Dual antiplatelet therapy	71.1%	65.2%	71.3%	0.074
Warfarin	7.4%	10.9%	7.2%	0.062
ACEI/A2 blocker	60.3%	60.3%	60.3%	0.999
Statins	83.3%	79.3%	83.5%	0.141
β-Blocker	67.7%	66.3%	67.8%	0.669

Values are n (%) or median (IQR).

MDRD-4, glomerular filtration rate calculated by MDRD Formula for glomerular filtration rate.

A2 blocker, angiotensin II receptor blocker; ACEI, ACE inhibitor; CAD, coronary artery disease; EF, ejection fraction; GRACE, Global Registry of Acute Coronary Events; MDRD, modification of diet in renal disease; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction; TNI, troponin.

of follow-up was 4.6 years, IQR 2.7–7.1 years. The median time for the stroke was 3.3±2.4 years since ACS. During this period 184 (4.4%) patients developed an ischaemic stroke, 153 (83.15%) had sinus rhythm and 31 (16.85%) had AF. Patients with stroke were older, with higher rates of hypertension, diabetes, a previous stroke and previous coronary artery disease.

CHA₂DS₂VASc and GRACE risk scores

The CHA₂DS₂VASc and GRACE risks scores have demonstrated a strong correlation ($r=0.685$, $p<0.001$). The discrimination of both risks scores to predict primary end point was adequate (c-index, 0.63 ± 0.02 and 0.60 ± 0.02 for CHA₂DS₂VASc and GRACE risks scores, respectively).

The HR to predict follow-up post-ACS ischaemic stroke was 1.36 (95% CI 1.27 to 1.48, $p<0.001$) for CHA₂DS₂VASc score and 1.02 (95% CI, 1.01 to 1.03, $p<0.001$) for GRACE risk score. In [table 2](#), the HR of each variable included in the CHA₂DS₂VASc and GRACE score was analysed.

Both risk scores demonstrated a risk gradient to predict post-ACS stroke: 1.5%, 2.7% and 5.3% for low, moderate and high CHA₂DS₂VASc risk groups, respectively, and 1.9%, 4.8% and 5.8% for low, moderate and high GRACE risk groups, respectively. [Figure 1](#) illustrates Kaplan-Meier curves for ischaemic strokes during the follow-up according to the risk stratification.

The negative predictive values of CHA₂DS₂VASc and GRACE risks scores were 98.48% (97–99.3%) and 98.07% (97.1–98.7%), respectively. After a reclassification analysis, there was no significant improvement in the global reclassification (NRI 1.98%, $p=0.69$).

The analysis, controlled for competitive events (death and stroke), confirmed that CHA₂DS₂VASc and GRACE risk scores were powerful predictors of stroke incidence during the follow-up (SHR 1.25; 95% CI 1.16 to 1.34; $p<0.001$, and HR 1.01; 95% CI 1.01 to 1.02; $p<0.001$, respectively).

DISCUSSION

We performed a comparative validation of GRACE and CHA₂DS₂VASc risk scores to predict ischaemic stroke after ACS. The main clinical finding of our study was that the discriminative ability of GRACE risk score to predict the primary end point was similar to CHA₂DS₂VASc, even in patients with AF.

Although the GRACE risk score was validated to quantify the risk of mortality and reinfarction in the acute phase¹⁷ or in the follow-up,^{11 12} little is known about its usefulness in predicting post-ACS stroke.¹⁸ Our study provides new evidence in this setting.

Stroke, a relatively rare complication after ACS, is associated with high mortality.^{5 18} It may occur due to a multitude of reasons, such as atherosclerotic disease and

Table 2 HR of each variable of GRACE and CHA₂DS₂VASc

Variables	HR	95% CI	P Value
GRACE			
Age	1.048	1.034 to 1.062	<0.001
History of congestive heart failure	1.748	1.234 to 2.478	0.002
History of myocardial infarction	1.359	0.909 to 2.032	0.135
Heart rate	1.006	0.999 to 1.012	0.070
Systolic blood pressure	1.005	1.001 to 1.010	<0.001
ST-segment depression	0.955	0.715 to 1.275	0.755
Creatinine	1.279	1.105 to 1.481	0.001
Elevated cardiac markers	1.197	0.813 to 1.762	0.362
No in-hospital PCI	1.563	1.168 to 2.093	0.003
CHA₂DS₂VASc			
C	1.858	1.315 to 2.626	<0.001
H	1.629	1.200 to 2.211	0.002
A ₂	2.723	1.880 to 3.945	<0.001
A ₁	2.245	1.544 to 3.264	<0.001
D	1.849	1.375 to 2.487	<0.001
S ₂	2.844	1.877 to 4.309	<0.001
Vasc	1.734	1.291 to 2.330	<0.001
Female sex	1.327	0.976 to 1.804	0.071

A₁, age between 65 and 74 years; A₂, age ≥75 years; C, congestive heart failure; D, diabetes; H, hypertension; GRACE, Global Registry of Acute Coronary Events; PCI, percutaneous coronary intervention; S₂, stroke; Vasc, vascular disease.

Figure 1 Kaplan-Meier curves illustrating survival according to CHA₂DS₂VASc and GRACE risk scores. Green: low risk, yellow: moderate risk and red: high risk.

thromboembolic events. Stroke represents one of the major causes of morbidity among hospital survivors of ACS. The identification of predictors for stroke in patients with ACS may help to optimise the treatment of high-risk patients. This could prevent fatal postdischarge consequences.

The incidence of stroke post-ACS has been estimated in several trials.¹⁹ This is highest in the first 5 days,¹ and subsequently it is reduced.^{18–20} Most of studies had assessed the incidence of stroke after ACS during the in-hospital phase, at 30 days or in the first year. In recent years, there have been some studies about the trends in the incidence of post-ACS stroke. Brammas *et al* published a reduction in the incidence of mortality in patients with post-ACS stroke, in the past few years, due to the improved treatment based on evidence.¹⁹

Clinical practice guidelines recommended risk stratification in ACS,^{21–22} in the acute phase and after hospital discharge, to improve the prognosis of these patients. To date, we have several risk scores to estimate the risk of thrombotic and thromboembolic events in ACS and AF, respectively. These risk scores have been developed and validated in the past years.

The 6-month GRACE¹¹ risk score is a simple tool for predicting mortality in patients with ACS. It was described in 2004. This is derived from the largest multinational registry and includes the complete spectrum of patients with ACS, based on independent predictors of outcome. The 6-month GRACE risk score was developed and validated with more than 20 000 patients, between 1999 and 2003, who were included in the GRACE registry (14 countries, 94 hospitals). This score allows us to calculate the probability of mortality during the first 6 months after discharge in all ACS spectrum (c-index higher than 0.70). The application of the GRACE risk score at admission was recommended by the clinical practice guidelines for risk stratification in ACS. The 6-month GRACE risk score was validated entirely across the wide range of current patients with ACS¹² and demonstrated superiority over other risk scores. Its predictive value was also further validated over 6 months (even in the 5-year follow-up).¹³

CHA₂DS₂VASc⁹ is a simple risk stratification schema to determine thromboembolic risk in patients with non-valvular AF. It was validated in 2009; 5333 ambulant and hospitalised patients with AF were enrolled from 2003 to 2004. The CHADS₂ is commonly used to assess risk of stroke, but CHA₂DS₂VASc scores have better discrimination of stroke risk, particularly in low-risk patients. Clinical practice guidelines recommended calculation of CHA₂DS₂VASc risk scores to determine whether patients with non-valvular AF need antithrombotic therapies for the prevention of stroke and systemic embolisation.

To date, no risk scores specifically estimate the risk of stroke after ACS. However, GRACE and CHA₂DS₂VASc risk scores could be useful in this setting. Our trial demonstrated that the accuracy of GRACE risk score was similar to the CHA₂DS₂VASc score to predict post-ACS

stroke. This is important because with only one tool, which was initially designed to assess thrombotic risk, we can predict thromboembolic risk after ACS. We can identify patients who will benefit from a more potent antithrombotic treatment at discharge. Although our results are striking, they are in line with other studies previously published, such as Barra *et al.*²³ Also this observational retrospective single-centre cohort study, with fewer patients (n=1,711 patients and post-ACS stroke rate of 4.3%) and a shorter follow-up (median 17.4±8.7 months), shows great predictive ability of the 6-month GRACE risk score (c-index 0.782±0.019). In our cohort, we showed there was no difference between GRACE and CHA₂DS₂VASc risk scores to predict the risk of stroke after ACS. We have identified the GRACE risk score as a new independent predictor of stroke post-ACS.

The stroke has been considered a complication after ACS; its frequency is especially increased in the first few months.¹⁹ One of the possible reasons that the GRACE risk score could predict the risk of stroke post-ACS is because many variables were previously demonstrated as independent predictors of post-ACS stroke. Thus, in recent years, predictors of post-ACS stroke have been identified in several trials: elderly, female sex, heart failure, coronary heart disease, AF, prior stroke, diabetes mellitus, timely revascularisation therapy, secondary prevention therapies and renal function.^{4 6 18 2 24-29}

Advanced age, a variable with great weightage in GRACE risk score, has proven to be a powerful risk factor for stroke in this population.^{2 28} Several reports have shown that impaired renal function is also an efficient predictor of stroke and systemic embolism, and in-hospital mortality of these patients. This was recently validated by Piccini *et al* in the ROCKET AF and ATRIAL Study Cohorts.²² Both elevated heart rate (more than 100 bpm)^{28 30} as well as a high Killip class¹⁷ at admission have demonstrated increased mortality, reinfarction as well as the greater possibility of post-ACS stroke. Also, the ST-segment changes on index ECG, specially STEMI, predicts more events.³¹ Likewise, the value of GRACE at admission, GRACE risk score and higher markers of myocardial damage are predictors to stroke post-ACS.^{17 31} Percutaneous coronary intervention during hospitalisation predicts a decreased risk of ischaemic stroke;³⁰ Van De Graaff *et al*⁶ showed a significant relationship between timely revascularisation therapy and risk of in-hospital ischaemic stroke. The patients with previous coronary heart disease and especially anterior myocardial infarction showed an increase in post-ACS stroke.³ Heart failure and reduced left ventricular ejection fraction^{4 18 32} had stronger association with mortality and also have been associated with increased risk of stroke after ACS. Because of this, although the GRACE score was not designed to determine the risk of stroke, it has good discriminative ability and a good correlation with CHA₂DS₂VASc to predict the primary end point. GRACE risk score included some

variables which have not been included in the CHA₂DS₂VASc score. The high-risk GRACE score patients are usually older patients with renal failure and more Killip; therefore, these patients could be at higher risk of stroke.

Clinical implications

In recent years, there has been increasing interest to show the risk of stroke after ACS, and the risk factors associated with it. The GRACE risk score could eventually contribute to a better risk stratification and help us make decisions about interventions to reduce stroke after ACS in high-risk patients. Nowadays, the estimation of cardiovascular risk and individualisation has become a priority. GRACE risk score is used in routine clinical practice for risk stratification to optimise the treatment. Our study shows a new utility to predict stroke in the follow-up post-ACS.

Limitations

These data must be interpreted in the context of this study's limitations. It is a retrospective analysis of clinical single centre data. Our small-sized sample should be considered the main limitation of this study. In fact, the relatively low absolute number of ischaemic stroke events during follow-up reinforces the need for more studies with larger cohorts of patients to confirm the usefulness of GRACE risk score. However, irrespective of its potential future clinical validation, our study has supported the applicability of GRACE risk score in patients with ACS prior to discharge. Moreover, as many patients who died during follow-up were not autopsied or previously observed at the emergency department, it is very hard, if not impossible in some cases, to know whether stroke was the cause of death. Therefore, the true incidence of stroke was probably underestimated.

Conclusions

The GRACE model is a clinical risk score that facilitates the identification of individual patients who are at high risk of stroke after ACS discharge. New therapeutic interventions that have the potential to limit preventable post-ACS stroke may have the greatest impact on this vulnerable population.

Acknowledgements The authors would like to thank all the staff members (physicians, nurses and auxiliary members) and fellows from the cardiology department and coronary care unit for their support.

Competing interests None.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

REFERENCES

- Moore T, Eriksson P, Stegmayr B. Ischemic stroke after acute myocardial infarction. *Stroke* 1997;28:762–7.
- Witt BJ, Brown RD Jr, Jacobsen SJ, *et al.* A community-based study of stroke incidence after myocardial infarction. *Ann Intern Med* 2005;143:785–92.
- Tanne D, Goldbourt U, Zion M, *et al.* Frequency and prognosis of stroke/TIA among 4808 survivors of acute myocardial infarction. The SPRINT Study Group. *Stroke* 1993;24:1490–5.
- Witt BJ, Ballman KV, Brown RD Jr, *et al.* The incidence of stroke after myocardial infarction: a meta-analysis. *Am J Med* 2006;119:354.e1–9.
- Budaj A, Flasińska K, Gore JM, *et al.* Magnitude of and risk factors for in-hospital and postdischarge stroke in patients with acute coronary syndromes: findings from a global registry of acute coronary events. *Circulation* 2005;111:3242–7.
- Van De Graaff E, Dutta M, Das P, *et al.* Early coronary revascularization diminishes the risk of ischemic stroke with acute myocardial infarction. *Stroke* 2006;37:2546–51.
- Maggioni AP, Franzosi MG, Santoro E, *et al.* The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. *N Engl J Med* 1992;327:1–6.
- Gage BF, Waterman AS, Shannon W, *et al.* Validation of clinical, classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. *JAMA* 2001;285:2864–70.
- Lip GY, Nieuwlaad R, Pisters R, *et al.* Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-bases approach: the euro heart survey on atrial fibrillation. *Chest* 2010;137:263–72.
- Poçi D, Hartford M, Karisson T, *et al.* Role of the CHADS2 score in acute coronary syndromes. Risk of subsequent death or stroke in patients with and without atrial fibrillation. *Chest* 2012;141:1431–40.
- Eagle KA, Lim MJ, Dabbous OH, *et al.*; GRACE Investigators. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. *JAMA* 2004;291:2727–33.
- Abu-Assi E, Ferreira-Gonzalez I, Ribera A, *et al.* Do GRACE (global registry of acute coronary events) risk scores still maintain their performance for predicting mortality in the era of contemporary management of acute coronary syndromes? *Am Heart J* 2013;160:826–34, e821–3.
- Fox KA, Carruthers KF, Dunbar DR, *et al.* Underestimated and under-recognized. The late consequences of acute coronary syndrome (GRACE UK–Belgium study). *Eur Heart J* 2010;31:2755–64.
- Fine JP, Gray R. A proportional hazards model for the subdistribution of a competing risk. *J Am Stat Assoc* 1999;94:496–509.
- Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. *Radiology* 1982;143:29–36.
- Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, *et al.* Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. *Stat Med* 2008;27:157–72.
- Barra S, Providência R, Lourenço Gomes P, *et al.* Predição do risco de evento cerebrovascular após um enfarte agudo de miocárdio. *Rev Port Cardiol* 2011;30:655–63.
- Brammås A, Jakobsson S, Ulvenstam A, *et al.* Mortality after ischemic stroke in patients with acute myocardial infarction. Predictors and trends over time in Sweden. *Stroke* 2013;44:3050–5.
- Moore T, Olofsson BO, Eriksson P. Ischemic stroke. Impact of a recent myocardial infarction. *Stroke* 1999;30:997–1001.
- Saczynski JS, Spencer FA, Gore JM, *et al.* Twenty-year trends in the incidence rates of stroke complicating acute myocardial infarction: Worcester Heart Attack Study. *Arch Intern Med* 2008;168:2104–10.
- Steg PG, James SK, Atar D, *et al.*; The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur Heart J* 2012;33:2569–619.
- Hamm CW, Bassand JP, Agewall S, *et al.*; ESC Committee for Practice Guidelines. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J* 2011;32:2999–3054.
- Barra S, Almeida I, Caetano F, *et al.* Stroke prediction with an adjusted R-CHA2DS2VASc score in a cohort of patients with a Myocardial Infarction. *Thromb Res* 2013;132:293–9.
- Piccini JP, Stevens SR, Chang Y, *et al.* Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 Index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. *Circulation* 2013;127:224–32.
- Providência R, Fernandes A, Paiva L, *et al.* Decreased glomerular filtration rate and markers of left atrial stasis in patients with nonvalvular atrial fibrillation. *Cardiology* 2013;124:3–10.
- Holzmann MJ, Aastveit A, Hammar N, *et al.* Renal dysfunction increases the risk of ischemic and hemorrhagic stroke in the general population. *Ann Med* 2012;44:607–15.
- Mostofsky E, Wellenius GA, Noheria A, *et al.* Renal function predicts survival in patients with acute ischemic stroke. *Cerebrovasc Dis* 2009;28:88–94.
- Wienbergen U, Weber MA, Muller CH, *et al.* Incidence, risk factors, and clinical outcome of stroke after acute myocardial infarction in clinical practice: mir and mitra study groups: myocardial infarction registry: maximal individual therapy in acute myocardial infarction. *Am J Cardiol* 2001;87:782–5, A788.
- [No authors listed]. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. *J Am Coll Cardiol* 1988;12(6 Suppl A):3A–13A.
- Sampson UK, Pfeffer MA, McMurray JJ, *et al.* Predictors of stroke in high-risk patients after acute myocardial infarction: insights from the VALIANT trial. *Eur Heart J* 2007;28:685–91.
- Park KL, Budaj A, Goldberg RJ, *et al.* Grace Investigators. Risk-prediction model for ischemic stroke in patients hospitalized with an acute coronary syndrome (from the global registry of acute coronary events [GRACE]). *Am J Cardiol* 2012;110:628–35.
- Jakobsson S, Bergström L, Björklund F, *et al.* Risk of ischemic stroke after an acute myocardial infarction in patients with diabetes mellitus. *Circ Cardiovasc Qual Outcomes* 2014;7:95–101.